The FDA has approved avanafil (Stendra) for the treatment of erectile dysfunction (ED), making it the first drug to be approved for the condition in nearly 10 years.
Manufactured by Vivus of Mountain View, Calif., avanafil met all primary efficacy endpoints in more than 1,200 men with ED who participated in clinical studies, according to a press release issued by the company. Significant improvements in erectile function were observed for all doses (50 mg, 100 mg, and 200 mg) compared with placebo.
“Patients and treating physicians continue to report significant dissatisfaction with current treatments of ED,” said Peter Tam, president of Vivus.
Continue Reading
It is recommended that avanafil be taken about 30 minutes before sexual activity. It should not be taken more than once per day.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.